FDA Sends Byondis Complete Response Letter Delaying Decision on HER2-Positive Breast Cancer Drug
Byondis submitted data on SYD985's activity from the Phase III TULIP trial, but the agency has requested additional information.
EQRx Slashes Headcount, Pipeline in Corporate 'Reset'
The firm is terminating three licensed programs, cutting 170 positions, seeking partnerships for one drug, and prioritizing development of a CDK4/6 inhibitor.
Bliss Biopharmaceutical, Eisai Partner to Develop Anti-HER2 ADC
The companies will codevelop BB-1701 as a treatment for HER2-expressing solid tumors through an option period, at which point Eisai may license the drug.
Scorpion Therapeutics Begins Trial of PI3Kα Inhibitor in HR-Positive, HER2-Negative Breast Cancer
Once a dose has been established, the trial will also include cohorts for gynecologic, head and neck, and solid tumors harboring a PI3Kα mutation.
Gilead Q1 Oncology Segment Sales Jump 59 Percent
Trodelvy sales increased 52 percent, Yescarta sales grew 70 percent, and Tecartus revenues increased 40 percent in Q1 2023 compared to the year-ago quarter.